menu search

CTIC / Why CTI BioPharma Stock Blasted 18% Higher Today

Why CTI BioPharma Stock Blasted 18% Higher Today
An analyst launches coverage of the company with an unequivocal buy recommendation. Read More
Posted: Jul 7 2022, 18:21
Author Name: The Motley Fool
Views: 111438

CTIC News  

CTI BioPharma skyrockets on acquisition by Sobi

By Proactive Investors
May 10, 2023

CTI BioPharma skyrockets on acquisition by Sobi

CTI BioPharma shares added almost 85% on the news that the company would be acquired by Stockholm-based hematology and immunology leader Swedish Orpha more_horizontal

Why Shares of CTI BioPharma Are Soaring Wednesday

By The Motley Fool
May 10, 2023

Why Shares of CTI BioPharma Are Soaring Wednesday

CTI BioPharma has one FDA-approved therapy, Vonjo, to treat a rare form of bone marrow cancer. The company is being bought at a 89% premium from its c more_horizontal

Why Is CTI BioPharma (CTIC) Stock Up 85% Today?

By InvestorPlace
May 10, 2023

Why Is CTI BioPharma (CTIC) Stock Up 85% Today?

CTI BioPharma (NASDAQ: CTIC ) stock is taking off on Wednesday after the company announced a major acquisition deal with Sobi. This deal has Sobi agre more_horizontal

CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.

By Barrons
May 10, 2023

CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.

Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio. more_horizontal

Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion

By Market Watch
May 10, 2023

Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion

Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a d more_horizontal

CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

By PRNewsWire
May 1, 2023

CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commer more_horizontal

VONJO Keeps CTI BioPharma A Buy

By Seeking Alpha
April 21, 2023

CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023

By PRNewsWire
April 12, 2023

CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023

SEATTLE, Wash. , April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development more_horizontal


Search within

Pages Search Results: